Table 2. Relationship Between Plasma levels and Demographic/ Clinical Factors.
| Therapeutic Level | Subtherapeutic/ Undetectable | p | ||
| N, % | 20 (56) | 16 (44) | ||
| Age in years (S.D.) | 43 .1 (11.0) | 37.6 (10.8) | 0.15a | |
| Male gender, n(%) | 16 (80) | 12 (75) | 0.51b | |
| Ethnicity, n | White British/other | 12 | 4 | 0.02b |
| Black | 7 | 13 | ||
| Diagnosis, n | Schizophrenia | 15 | 12 | 0.29b |
| Schizoaffective | 5 | 2 | ||
| Other | 0 | 2 | ||
| Antipsychotic, n | Olanzapine or Amisulpride | 17 | 8 | 0.03b |
| Other | 3 | 8 | ||
| Length of treatment with current antipsychotic in months (S.D.) | 79 (48) | 30 (32) | 0.001c | |
| Average dose, CPZ equiv12 mg/day (S.D.) | 664 (294) | 487 (138) | 0.06a | |
| Average level, %min range(S.D.) | 354 (232) | 37 (25)* | ||
| PANSS, mean (SD) | Positive | 20.2.4 (9.9) | 23.1 (10.0) | 0.38c |
| Negative | 17.4 (7.1) | 16.1 (6.9) | 0.63a | |
| General | 36.2 (12.2) | 41.7 (15.0) | 0.24c | |
| Total | 73.8 (22.8) | 80.3 (27.8) | 0.58c | |
| Admission, n (%) | 1 (5) | 3 (19) | 0.19d | |
| Antipsychotic plasma levels measured in the previous year | 0 | 1 | ||
a
Independent samples t-test
b
Fisher’s Exact test
c
Mann-Whitney
d
Mantel-Cox log rank
*
undetectable values not included in calculation